<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/326EF7F4-5944-472D-BC94-2CA4484AEE74"><gtr:id>326EF7F4-5944-472D-BC94-2CA4484AEE74</gtr:id><gtr:name>University of Groningen</gtr:name><gtr:address><gtr:line1>Postbus 72</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/57150975-2FFC-442F-A99E-ABD25A46F8D2"><gtr:id>57150975-2FFC-442F-A99E-ABD25A46F8D2</gtr:id><gtr:name>Pasteur Institute, Paris</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/49C44558-A75A-448F-9BF7-3F947FA67EB7"><gtr:id>49C44558-A75A-448F-9BF7-3F947FA67EB7</gtr:id><gtr:name>Technical University of Munich</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Immunity and Infection</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/326EF7F4-5944-472D-BC94-2CA4484AEE74"><gtr:id>326EF7F4-5944-472D-BC94-2CA4484AEE74</gtr:id><gtr:name>University of Groningen</gtr:name><gtr:address><gtr:line1>Postbus 72</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/57150975-2FFC-442F-A99E-ABD25A46F8D2"><gtr:id>57150975-2FFC-442F-A99E-ABD25A46F8D2</gtr:id><gtr:name>Pasteur Institute, Paris</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/49C44558-A75A-448F-9BF7-3F947FA67EB7"><gtr:id>49C44558-A75A-448F-9BF7-3F947FA67EB7</gtr:id><gtr:name>Technical University of Munich</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/1BAE1842-93F0-4C9E-850D-7BD60FDF8914"><gtr:id>1BAE1842-93F0-4C9E-850D-7BD60FDF8914</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Balfe</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/92EB47C3-A7C8-47C9-82FE-759E0D5DEBE0"><gtr:id>92EB47C3-A7C8-47C9-82FE-759E0D5DEBE0</gtr:id><gtr:firstName>Jane</gtr:firstName><gtr:otherNames>Alison</gtr:otherNames><gtr:surname>McKeating</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0801976"><gtr:id>01325D12-4E5A-4733-BA86-54E28AB94E80</gtr:id><gtr:title>Mechanisms of Hepatitis C virus induced hepatocyte injury.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801976</gtr:grantReference><gtr:abstractText>HCV disease is a global problem, with over 2% of the world?s population infected, some 180 million people. Although the disease may take decades to progress, the majority of chronically infected people will eventually show signs of liver damage. In the last few years the incidence of HCV-associated liver failure has increased considerably in the U.K. and several studies have predicted a further 50 - 100% increase in the next decade. HCV-associated liver failure is now the leading indicator for liver transplantation in the UK. Unfortunately the only current therapy (pegylated interferon + ribavirin) is expensive, has significant side effects and is often ineffective. Hence, there is an urgent need for new approaches to treat this disease.

One of the prime functions of the liver is the synthesis of bile, which is kept separate from the blood supply by a polarized barrier between the biliary vessels and the rest of the liver. Several manifestations of liver injury associated with HCV infection involve some degree of failure of this biliary system, leading to the liver being damaged by bile acid. HCV entry into cells involves proteins involved in cell polarization, notably the tight junction protein Claudin?1. We have shown that HCV infected cells have an altered polarity and express excessive quantities of Vascular Endothelial Growth Factor (VEGF), a protein which disrupts cell polarization. Depolarisation is mediated via two structural components of the virus, the envelope proteins E1 and E2, that sequester Claudin-1 protein within the cell and stimulate VEGF expression. Treatment of HCV infected cultures with an antibody that inhibits VEGF activity abrogates new rounds of HCV infection, providing an exciting new avenue for antiviral intervention. It is worth noting that, if this approach is validated during the course of this study, suitable VEGF antagonists are already approved for the treatment of various advanced cancers, and we would anticipate the process of drug development to be considerably accelerated.</gtr:abstractText><gtr:technicalSummary>Hepatitis C virus (HCV) primarily infects hepatocytes within the liver, with the majority of infected subjects developing progressive disease including chronic hepatitis, cirrhosis and hepatocellular carcinoma. However, the mechanisms underlying liver injury are poorly defined. Many tissues in the body contain polarised cells and hepatocytes are known to polarise with tight junctions separating their apical canalicular and basolateral domains. Hepatic polarity is critical to the function of the liver. Cholestasis occurs when tight junctions lose function permitting the leakage of proteins and bile acids between apical and basal compartments. Recent advances allowing the propagation of HCV in cell culture have demonstrated that viral infection disrupts hepatocellular tight junctions and induces vascular endothelial growth factor (VEGF) expression. VEGF is an angiogenic factor expressed in many tumours. We have shown that VEGF can disrupt hepatocellular tight junctions and promote HCV infection of polarized HepG2 cells. Current evidence suggests that the viral encoded E1E2 glycoproteins induce the relocalisation of tight junction proteins in a VEGF-dependent manner. We propose to investigate the effect(s) of HCV glycoproteins, cloned from subjects with or without cholestasis, on TJ protein localization, function and VEGF expression. We will evaluate both the VEGF-dependency of virus induced changes in hepatocyte polarity and the efficacy of VEGF antagonists on HCV induced changes in cellular polarity. Several VEGF antagonists are under evaluation for the treatment of diverse cancers. These data suggest that targeting VEGF may provide a new approach for the treatment of HCV infection and related HCC metastasis.</gtr:technicalSummary><gtr:fund><gtr:end>2012-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>348254</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Immune Regulation</gtr:department><gtr:description>MRC centre for Immune Regulation</gtr:description><gtr:id>9E33AE3E-7B42-4688-88BC-7F90BFD24310</gtr:id><gtr:impact>Many of the publications we generated between 2006 and 2012 used the MRC centre facilities.</gtr:impact><gtr:outcomeId>pJHufLu7DJ7-1</gtr:outcomeId><gtr:partnerContribution>Provision of key core technologies and expertise</gtr:partnerContribution><gtr:piContribution>Access to shared facilities and provision of expertise</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Technical University of Munich</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>HEPacute</gtr:description><gtr:id>EE49FD87-564C-4225-8DD9-C29FBCA30CF0</gtr:id><gtr:impact>None to date</gtr:impact><gtr:outcomeId>pQnjFEX6hJH-1</gtr:outcomeId><gtr:partnerContribution>Access to European HCV samples</gtr:partnerContribution><gtr:piContribution>FP7 network to investigate corrrelates of viral clearance in acute infection</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Margaret Ashcroft - To study the role of hypoxia on hepatitis C and B replication.</gtr:description><gtr:id>AE11E52E-E5B4-4B01-AA4B-75BF4E2AEB14</gtr:id><gtr:impact>Wilson, G., Brimacombe, C.L., Rowe, I.A., Reynolds, G.M., Fletcher, N.F., Stamataki, Z., Bhogal, R., Simoes, M., Ashcroft, M., Afford, S.C., Mitry, R., Dhawan, A., Mee, C.J., Hubscher, S.G., Balfe, P., and McKeating, J.A. (2012). A dual role for hypoxia factor 1-a in the hepatitis C virus lifecycle and hepatoma migration. J. Hepatology 56: 803-9.</gtr:impact><gtr:outcomeId>QSDbYFTifsM-1</gtr:outcomeId><gtr:partnerContribution>Provision of HIF-1a expression vectors and inhibitors.</gtr:partnerContribution><gtr:piContribution>Provide viral hepatitis expertise and clinical material.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Groningen</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Sven IJzendoorn - To study the role of hepatocyte polarity in hepatitis C virus infection.</gtr:description><gtr:id>CFD44270-EBE5-4155-BB39-DA7E79951501</gtr:id><gtr:impact>Harris, H.J., Clerte, C., Fraquhar, M,J., Goodall, M., Hu, K., Rassam, P., Dosset, P., Wilson, G.K., Balfe, P., IJzendoorn, S.C., Milhiet, P.E. and McKeating, J.A. (2013). Hepatoma polarization limits CD81 and hepatitis C virus dynamics. Cellular Micro 15: 430-45. 

Mee, C. J., Harris, H. J., Farquhar, M. J., Wilson, G., Reynolds, G., Davis, C., van, IJzendoorn, S. C., Balfe, P. &amp;amp; McKeating, J. A. (2009). Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells. J. Virology 83, 6211-6221. 

Farquhar, M. J., Harris, H. J., Diskar, M., Jones, S., Mee, C. J., Nielsen, S. U., Brimacombe, C. L., Molina, S., Toms, G. L., Maurel, P., Howl, J., Herberg, F. W., van Ijzendoorn, S. C., Balfe, P. &amp;amp; McKeating, J. A. (2008). Protein kinase A-dependent step(s) in hepatitis C virus entry and infectivity. J Virology 82, 8797-8811.</gtr:impact><gtr:outcomeId>bbsF4mb9JoH-1</gtr:outcomeId><gtr:partnerContribution>Hepatocyte polarity expertise</gtr:partnerContribution><gtr:piContribution>Viral hepatitis expertise.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Health and Medical Research (INSERM)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Thomas Baumert - To study the mechanism of hepatitis C virus entry into polarized hepatocytes.</gtr:description><gtr:id>FA75866C-DDDC-4B76-865C-686F69D48BF6</gtr:id><gtr:impact>Zona, L., Lupberger, J., Thumann, C., Ahmed-Adrar, N.S., Thumann, C., Harris, H.J., Barnes, A., Florentin, J., Taware, R.G., Xiao, F., Turek, M., Durand, S.C., Duong, F.H., Heim, M.H., Cosset, F-L., Hirsch, I., Brino, L., Zeisel, M.B., Le Naour, F., McKeating, J.A. and Baumert, T.F. (2013). HRas signal transduction mediates hepatitis C virus entry by triggering the assembly of the host tetraspanin receptor complex. Host Cell and Microb 13: 302-13.
Fofana, I., Zona, L., Thumann, C., Heydmann, L., Durand, S.C., Lupberger, J., Blum, H.E., Pessaux, P, Gondeau, C., Reynolds, G.M., McKeating, J.A., Grunert, F., Thompson, J., Zeisel, M.B., and Baumert, T.F. Functional analysis of claudin-6 and claudin-9 as entry factors for hepatitis C virus infection of human hepatocytes using monoclonal antibodies. J Virol, in press.
Farquhar, M. J., Hu, K., Harris, H.J., Davis, C., Brimacombe, C.L., Baumert, T.F., Rappoport, J.Z., Balfe, P., and McKeating, J.A. (2012). Hepatitis C virus promotes CD81 and claudin-1 endocytosis. J Virology 86: 4305-16.
Fletcher, N.F., Wilson, G.K., Murray, J., Hu, K., Lewis, A., Reynolds, G., Stamataki, Z., Meredith, L.W., Rowe, I.A., Luo, G., Lopez-Ramirez, M.A., Baumert, T. F., Weksler, B., Couraud, P.O., Kim, S.K., Romero, I.A., Jopling, C., Morgello, S., Balfe, P., and McKeating, J.A. (2012). Hepatitis C virus infection of blood brain barrier endothelial cells. Gastroenterology 142: 634-643.
Lupberger, J., Zeisel, M.B., Xiao, F., Thumann, C., Fofana, I., Zona, L., Davis, C., Mee, C.J., Turek, M., Gorke, S., Royer, C., Fischer, B., Zahid, M.N., Lavillette, D., Fresquet, J., Cosset, F-L., Rothenberg, S.M., Pietschmann, T., Patel, A.H., Pessaux, P., Doffeol, M., Raffelsberger, W., Poch, O., McKeating, J.A., Brino, L., and Baumert, T.F. (2011). EGF receptor and EphA2 are hepatitis C virus host entry factors and targets for antiviral therapy. Nat Med, 17: 589-95.
Syder, A.J, Lee, H., Zeisel, M.B., Grove, J., Soulier, E., Macdonald, J., Chow, S., Chang, J., Baumert, T.F., McKeating, J.A., McKelvy, J., Wong-Staal, F. (2011). Small molecule scavenger receptor B1 antagonists are potent HCV entry Inhibitors. J. Hepatology, 54, 48-55.
Brimacombe, C., Grove, J., Meredith, L., Hu, K., Syder, A.J., Flores, M.F., Timpe, J., Krieger, S.E., Baumert, T.F., Tellinghuisen, T.L., Wong-Staal, F., Balfe, P., and McKeating, J.A. (2011). Neutralizing antibody resistant hepatitis C virus cell-to-cell transmission. J.Virology, 85, 596-605. 
Fletcher, N.F., Yang, J.P., Farquahr, M.F., Hu, K., Davis, C., He, Q., Dowd, K., Ray, S.C., Krieger, S.E., Baumert, T.F., Balfe, P., Wong-Staal, F., and McKeating, J.A. (2010). Hepatitis C virus infection of neuroepithelioma cell lines. Gastroenterology, 139: 1365-1374.
Fofana, I., Krieger, S.E., Grunert, F., Glauben, S., Xiao, F., Fafi-Kremer, S., Soulier, E., Royer, C., Mee, C.J., McKeating J.A., Dragic, T., Schuster, C., Thompson, J., and Baumert, T.F. (2010). Monoclonal anti-Claudin 1 antibodies for the prevention of hepatitis C virus infection. Gastroenterology, 139:953-64.
Krieger, S.E., Zeisel, M.B, Davis, C., Thumann, C., Harris, H.J., Schnober, E.K., Mee, C.J., Soulier, E., Lambotin, M., Grunert, F., Loan Dao Thi, V., Dreux, M., Cosset, F-L., McKeating, J.A., Schuster, C., and Baumert, T.F (2010). Inhibition of hepatitis C virus infection by anti Claudin antibodies is mediated by neutralization of E2-CD81-Claudin 1 association(s). Hepatology, 51:1144-57.
Kapadia, S. B., Barth, H., Baumert, T., McKeating, J. A. &amp;amp; Chisari, F. V. (2007). Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virology 81, 374-383.</gtr:impact><gtr:outcomeId>egXQirWTpMc-1</gtr:outcomeId><gtr:partnerContribution>Complementary viral expertise.</gtr:partnerContribution><gtr:piContribution>Provide imaging expertise of viral receptor trafficking.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pasteur Institute, Paris</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Thomas Krey - To study the mechanism of hepatitis C virus neutralization.</gtr:description><gtr:id>DD8064DB-23FB-4F9B-A68C-D81AE33DEA2D</gtr:id><gtr:impact>'Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies.' &amp;nbsp;Meola A, Tarr AW, England P, Meredith LW, McClure CP, Foung SK, McKeating JA, Ball JK, Rey FA, Krey T,&amp;nbsp;J Virol, 89: 2170-81, 2015.

'An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission.' &amp;nbsp;Tarr AW, Lafaye P, Meredith L, Damier-Piolle L, Urbanowicz RA, Meola A, Jestin JL, Brown RJ, McKeating JA, Rey FA, Ball JK, Krey T,&amp;nbsp;Hepatology, 58: 932-9, 2013.</gtr:impact><gtr:outcomeId>YwJVq8CXg2v-1</gtr:outcomeId><gtr:partnerContribution>Structural biologist</gtr:partnerContribution><gtr:piContribution>Viral hepatitis Expertise.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Dan Tennant - To study the role of hypoxia on hepatitis C and B replication.</gtr:description><gtr:id>7CF57158-18F0-4ECB-A478-F45236B39EC2</gtr:id><gtr:impact>Wilson, G., Tennant, D and McKeating J.A (2013). Hypoxia, viruses and liver injury. J Hepatology, invited review. 

A manuscript is currently under preparation and planning to submit MRC Project grant next year.</gtr:impact><gtr:outcomeId>iz7gNG6px9t-1</gtr:outcomeId><gtr:partnerContribution>Provision of hypoxia expertise.</gtr:partnerContribution><gtr:piContribution>Provide viral hepatitis expertise and clinical material.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>David Adams - To study hepatitis C virus pathogenesis</gtr:description><gtr:id>37840F18-CFDC-4B79-A56F-F27D80E4856C</gtr:id><gtr:impact>Stamataki, Z., Tilakaratne, S., Adams, D.H., and McKeating, J.A. (2011). Rituximab treatment in hepatitis C infection: an in vitro model to study the impact of B cell depletion on virus infectivity. PLoS One 6(9):e25789.

Rowe, I.A., Wilson, G.K., Galsinh, S.K., Durrant, S., Lazar, C., Branza-Nichita, N., Bicknell, R., Adams, D.H., Balfe,P., and McKeating, J.A. (2013). Paracrine signals from liver sinusoidal endothelium regulate HCV replication. Hepatology, in press.

Fletcher, N.F., Sutaria, R., Juandy, J., Barnes, A., Blahova, M., Hu, K., Cosset, F-L., Balfe, P., Adams, D.H., Curbishley, S,M., Bertoletti, A. and McKeating, J.A. Activated macrophages promote hepatitis C virus entry in a tumor necrosis factor-dependent manner. Hepatology, in press.

Stamataki, Z., Shannon-Lowe, C., Shaw, J., Mutimer, D., Rickinson, A. B., Gordon, J., Adams, D. H., Balfe, P. &amp;amp; McKeating, J. A. (2009). Hepatitis C virus association with peripheral blood B lymphocytes potentiates viral infection of liver-derived hepatoma cells. Blood 113, 585-593.

Reynolds, G. M., Harris, H. J., Jennings, A., Hu, K., Grove, J., Lalor, P. F., Adams, D. H., Balfe, P., Hubscher, S. G. &amp;amp; McKeating, J. A. (2008). Hepatitis C virus receptor expression in normal and diseased liver tissue. Hepatology 47, 418-427.

Lai, W. K., Curbishley, S. M., Goddard, S., Alabraba, E., Shaw, J., Youster, J., McKeating, J. A &amp;amp; Adams, D. H. (2007). Hepatitis C is associated with perturbation of intrahepatic myeloid and plasmacytoid dendritic cell function. J Hepatology 47, 338-347.

Grants: 
Liver Biomedical Research Unit to study Immune and cell therapy of liver disease. Investigators: Adams, McKeating, Newsome, Stewart, Johnson, Young. Awarding Body: National Institute of Health Research (UK). Funds: &amp;pound;6.35 million. Dates: 2012-2017.</gtr:impact><gtr:outcomeId>kvDZ4YBt82L-1</gtr:outcomeId><gtr:partnerContribution>Immunological expertise</gtr:partnerContribution><gtr:piContribution>Viral hepatitis Expertise.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Big Bang Fair</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>52B1BEA2-821F-4337-B39F-FF25A5CF239D</gtr:id><gtr:impact>Ran activity at the &amp;quot;Big Bang Fair&amp;quot; - a national science fair at the Birmingham NEC targeted to School years 7 - 11 with &amp;gt; 15,000 attendees.
Also acted as Judge for national science scheme entries.</gtr:impact><gtr:outcomeId>56dc649c6281b3.75655789</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Research Seminar, WIMM, Oxford</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5C76F4DA-E726-4A39-BFCD-9DBB5A885B96</gtr:id><gtr:impact>Research Seminar</gtr:impact><gtr:outcomeId>58c6488548d115.25385341</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>STEMnet ambassador scheme</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>1B5CC9BD-2A9C-4159-A893-DA3A22D56443</gtr:id><gtr:impact>&amp;gt;20 ambassadors from MDS are now actvively engaged in visits to West Midlands Schools and MDS has become the largest group at UoB to send people out on these visits. In the last year 45 visits were made and we estimate &amp;gt;1,000 children (and their teachers) were visited.

Several of our ambassadors are visiting schools for the third year running and the schools appreciate the presence of UoB in their community</gtr:impact><gtr:outcomeId>s5J9nVTQroN</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited speaker</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>ACBC67E2-2A15-407A-85DB-D52C320830C3</gtr:id><gtr:impact>Plenary speaker at Conference</gtr:impact><gtr:outcomeId>58c645fbc43461.22957529</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School prize giving &amp; lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>53481B3E-8244-42DC-AF0B-EAAE4ED30473</gtr:id><gtr:impact>Gave talk on women in science, careers and research. Presented School prizes

School reported strengthening of science curriculum</gtr:impact><gtr:outcomeId>79A558E6AB0</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Pint of Science lectures</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>F2A4E196-94B0-48CF-9E3E-677134E7BAFF</gtr:id><gtr:impact>Pint of Science is an international initiative to enhance public understanding of science. We took part in the inaugural series in Birmingham in 2015.</gtr:impact><gtr:outcomeId>56dc63d8ed3de5.43517943</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School science weeks</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>84B1BB11-CCAE-46CF-8F62-C41C582917CF</gtr:id><gtr:impact>Series of hands on experience of microbiology for primary school children.

School reports improved KS2 results and better understanding of health among children</gtr:impact><gtr:outcomeId>10DD0C07164</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Careers fairs</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>06EE2F5F-7CCC-4D07-A2FD-4996A9DECF32</gtr:id><gtr:impact>Had several students apply to UoB on the basis of our presentations. To date these careers talks have been give to over 500 17-18 year olds

Repeat visits invitations from all schools involved. several work experience students have applied for time in our department on the basis of these activities.</gtr:impact><gtr:outcomeId>mMbrF7GoAtN</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010,2011,2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Flak International Meeting, basic science to clinical practice</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A6EB0E62-B05A-4147-BAA9-AAD7B8DF9328</gtr:id><gtr:impact>Plenary session at policy forum</gtr:impact><gtr:outcomeId>58c647faaee9a7.18377029</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visits and lectures</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>9167CCFE-17C7-4B36-8EEB-F0158B5B5DD3</gtr:id><gtr:impact>Virology talks to 6th form students, with description of research career and role of women in science.

Teachers reported that several students chose to study Biology or Medicine as a result of these talks (indeed one of these students is now on our course in Birmingham).</gtr:impact><gtr:outcomeId>E3C3AD3768C</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2007,2008,2009,2010,2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Research Seminar, King's College London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BB455A0D-D74A-49D4-9253-07B5C59130B2</gtr:id><gtr:impact>Invited research Seminar</gtr:impact><gtr:outcomeId>58c648c2ba9495.83334161</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Research Seminar, Freiburg</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>74009E3A-8193-4889-88CF-467F6423B08F</gtr:id><gtr:impact>Research seminar and collaborative meeting</gtr:impact><gtr:outcomeId>58c646d6120027.84249718</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Research Seminar, IAS, TUM, Munich</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9FA3E510-D514-4599-9ECB-4C7B7883C720</gtr:id><gtr:impact>Research seminar</gtr:impact><gtr:outcomeId>58c6479a463c71.41528492</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>PathCo Meeting, Sienna</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AC66C18D-DFAF-4145-B384-AC80C6A2C9E6</gtr:id><gtr:impact>Chair of Scientific session and presenter</gtr:impact><gtr:outcomeId>58c64731269821.92761286</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Research Seminar, Institute Pasteur</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>09E96C40-7CD2-4314-B21D-A19C51566D7C</gtr:id><gtr:impact>Invited speaker</gtr:impact><gtr:outcomeId>58c6484a3242c3.99171297</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>HepCar Kick off meeting</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>586D7107-5050-4C90-9969-4A4CBB1E73B5</gtr:id><gtr:impact>Address to Meeting, chair of Research committee</gtr:impact><gtr:outcomeId>58c646797a3507.36822757</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>189694</gtr:amountPounds><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Grant (ROTRF)</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Roche Organ Transplantation Research Foundation (ROTRF)</gtr:fundingOrg><gtr:id>3B865A51-7C40-40BC-B12A-3199B1676E32</gtr:id><gtr:outcomeId>HVuML4fP9Kr</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>329505</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>Research Grant (FP7, Hepacute)</gtr:description><gtr:end>2014-04-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>4D91E92A-8487-414A-8F1E-457B02B566A8</gtr:id><gtr:outcomeId>QR2vp6W43sM</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>240000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clarendon Scholarship</gtr:description><gtr:end>2020-09-02</gtr:end><gtr:fundingOrg>University of Oxford</gtr:fundingOrg><gtr:id>A075D64C-2CB4-4D1A-9042-B8F9FF301615</gtr:id><gtr:outcomeId>58c64a8fed6787.24082603</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>242000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Research Fellowship</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>200113/Z/15/Z</gtr:fundingRef><gtr:id>B92D2871-FD7B-48A8-A4CE-20564AD4EBCA</gtr:id><gtr:outcomeId>58c649888ab7c3.41269656</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>69633</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BCH Research Studentship</gtr:description><gtr:end>2013-12-02</gtr:end><gtr:fundingOrg>BCH Charities</gtr:fundingOrg><gtr:fundingRef>BCHRF253</gtr:fundingRef><gtr:id>64CC6D66-F602-43D6-91A2-1C8B26CE9412</gtr:id><gtr:outcomeId>FfUeJwDs4yv</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>241000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research grant (Pfizer)</gtr:description><gtr:end>2010-04-02</gtr:end><gtr:fundingOrg>Pfizer Ltd</gtr:fundingOrg><gtr:id>CF98F92B-E8F0-480E-B711-A99DAA6AA4EC</gtr:id><gtr:outcomeId>1135416B3600</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2008-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1600000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Senior Investigator Award</gtr:description><gtr:end>2022-07-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>99BEEEB8-9D82-452C-A9D0-8C8BA39AE2B3</gtr:id><gtr:outcomeId>58c64a2bc1e025.72988672</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>A culture system to evaluate HCV infection of polarized hepatoma cell lines</gtr:description><gtr:id>2BA91270-0F7E-464D-926D-9501D804E9B3</gtr:id><gtr:impact>Several groups are now re-assessing their infection models to take into account the effects of cell polarization.</gtr:impact><gtr:outcomeId>23C9C2F8228</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Polarized HepG2 infection system</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>An assay was developed to quantify the degree of direct cell to cell transfer of HCV in the presence of neutralising antibodies</gtr:description><gtr:id>D338B83A-7C82-4F98-BEFD-011C19B08466</gtr:id><gtr:impact>These experiments have led to several groups re-assessing the likely efficacy of mAb based therapies</gtr:impact><gtr:outcomeId>CA84CC9CBBB</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Assay for cell to cell transmission of HCV</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>22C00A2B-861E-4D39-AAED-1756E88F274F</gtr:id><gtr:title>Assessing interactions between HLA-DRB1*15 and infectious mononucleosis on the risk of multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Multiple sclerosis (Houndmills, Basingstoke, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af39e4662c93fc98be2a0468db12b545"><gtr:id>af39e4662c93fc98be2a0468db12b545</gtr:id><gtr:otherNames>Disanto G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1352-4585</gtr:issn><gtr:outcomeId>585d5a7b5b53e3.97506368</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C7CADB33-3BC6-4443-9E96-30D7F21A8184</gtr:id><gtr:title>DNase hypersensitive sites and association with multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af39e4662c93fc98be2a0468db12b545"><gtr:id>af39e4662c93fc98be2a0468db12b545</gtr:id><gtr:otherNames>Disanto G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>585d5a25ef8b59.77419678</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C0B3DA00-2355-4A42-A9B9-5441FBBDA033</gtr:id><gtr:title>Lentiviral hepatitis B pseudotype entry requires sodium taurocholate co-transporting polypeptide and additional hepatocyte-specific factors.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a2b568e567c92b96b0359b6a2750e89"><gtr:id>3a2b568e567c92b96b0359b6a2750e89</gtr:id><gtr:otherNames>Meredith LW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>56cddd20d4a5d7.19537286</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>28BBA261-EC7C-4F47-9151-710FA704CF38</gtr:id><gtr:title>Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody.</gtr:title><gtr:parentPublicationTitle>Nature biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/39fa156771b11e594ede29bd67666cdf"><gtr:id>39fa156771b11e594ede29bd67666cdf</gtr:id><gtr:otherNames>Mailly L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1087-0156</gtr:issn><gtr:outcomeId>56cddd213f3151.63104440</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16912FD1-A1CA-4879-AEA4-5688DA76F84C</gtr:id><gtr:title>Paracrine signals from liver sinusoidal endothelium regulate hepatitis C virus replication.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68859e2678f8b3f51bdc173b90573c7b"><gtr:id>68859e2678f8b3f51bdc173b90573c7b</gtr:id><gtr:otherNames>Rowe IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>pm_15282_22_23775568</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2463B6A1-7D81-400A-A5F4-9B86175A9DCA</gtr:id><gtr:title>Multiple effects of silymarin on the hepatitis C virus lifecycle.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/87ea4bcc15f1d3af2793c8d32d5aa836"><gtr:id>87ea4bcc15f1d3af2793c8d32d5aa836</gtr:id><gtr:otherNames>Wagoner J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>nQCppDFNcLp</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6BDE21C8-1703-4425-A808-E2F29CFAFF2A</gtr:id><gtr:title>The complexities of hepatitis C virus entry.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2fca135231efdea352f7b6008279f4f8"><gtr:id>2fca135231efdea352f7b6008279f4f8</gtr:id><gtr:otherNames>Balfe P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>UqBbicTw5De</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E48ABF6-B93C-4CEA-B20C-BEFCE6FDFA31</gtr:id><gtr:title>Vitamin D receptor binding, chromatin states and association with multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af39e4662c93fc98be2a0468db12b545"><gtr:id>af39e4662c93fc98be2a0468db12b545</gtr:id><gtr:otherNames>Disanto G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>585d5ab0096c70.51770567</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F707F332-BC04-43CD-BB4D-4E7CE0E4309A</gtr:id><gtr:title>Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6940caa80bc023cd10f951b128d76eb"><gtr:id>d6940caa80bc023cd10f951b128d76eb</gtr:id><gtr:otherNames>von Hahn T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>2A44B389445</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>248E451B-1F22-4F3E-8F3F-547C2AAD9E90</gtr:id><gtr:title>Activated macrophages promote hepatitis C virus entry in a tumor necrosis factor-dependent manner.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e28545930847fbdf21015e10fbfd11d1"><gtr:id>e28545930847fbdf21015e10fbfd11d1</gtr:id><gtr:otherNames>Fletcher NF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>pm_540e13ce13c1bc11e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2C2E97E-2A06-4673-B1B3-3CD39F257356</gtr:id><gtr:title>Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6940caa80bc023cd10f951b128d76eb"><gtr:id>d6940caa80bc023cd10f951b128d76eb</gtr:id><gtr:otherNames>von Hahn T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>C9A615E6F0C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BCC90BB8-AD95-4C7A-90CA-BFA13EC99AA8</gtr:id><gtr:title>Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc3759cd1489c0e1829b6d5b6d53c0b7"><gtr:id>fc3759cd1489c0e1829b6d5b6d53c0b7</gtr:id><gtr:otherNames>Stamataki Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>A74A84AAF65</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22B4B543-2D9A-4D39-9615-D89D314C6603</gtr:id><gtr:title>Superinfection exclusion in cells infected with hepatitis C virus.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ff4c4c49807475824c370c30580373b"><gtr:id>0ff4c4c49807475824c370c30580373b</gtr:id><gtr:otherNames>Tscherne DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>E93A14F2876</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17160E08-36DF-461A-9401-C51CFD5AC022</gtr:id><gtr:title>Hepatitis C virus receptor expression in normal and diseased liver tissue.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c7bc4f2814d38789cf0c55fc1811ac9"><gtr:id>5c7bc4f2814d38789cf0c55fc1811ac9</gtr:id><gtr:otherNames>Reynolds GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>7E199E2FB1B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73BF708F-6C34-4A76-9EEF-D14A47F98E13</gtr:id><gtr:title>Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe40ce492da64d8686da83c7038b7e65"><gtr:id>fe40ce492da64d8686da83c7038b7e65</gtr:id><gtr:otherNames>Grove J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>D3014BC1656</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>666E7C2A-E773-4599-88E7-6490ED8CF7B7</gtr:id><gtr:title>Breastfeeding and multiple sclerosis relapses: a meta-analysis.</gtr:title><gtr:parentPublicationTitle>Journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63e5b7621621fb6aaaf3c2def012af64"><gtr:id>63e5b7621621fb6aaaf3c2def012af64</gtr:id><gtr:otherNames>Pakpoor J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0340-5354</gtr:issn><gtr:outcomeId>585d5aacf1b5b2.98099632</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63872FCE-D0A0-44E2-9173-B1833BFEE59F</gtr:id><gtr:title>CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72c9d36662cb20471af6a26537b90de2"><gtr:id>72c9d36662cb20471af6a26537b90de2</gtr:id><gtr:otherNames>Harris HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>7B51DA9E955</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9FFC6EA4-5B08-4C26-8910-693BBA150D54</gtr:id><gtr:title>The Neutralizing Activity of Anti-Hepatitis C Virus Antibodies Is Modulated by Specific Glycans on the E2 Envelope Protein</gtr:title><gtr:parentPublicationTitle>Journal of Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f1d6c7ceb05f9f1de93d7380efc1158"><gtr:id>9f1d6c7ceb05f9f1de93d7380efc1158</gtr:id><gtr:otherNames>Helle F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>4F104B7B9F5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>723CA186-DAB9-4851-8085-41ED724D3143</gtr:id><gtr:title>Hepatoma cell density promotes claudin-1 and scavenger receptor BI expression and hepatitis C virus internalization.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5181c7d6d325ef99611d4b8158fa5a75"><gtr:id>5181c7d6d325ef99611d4b8158fa5a75</gtr:id><gtr:otherNames>Schwarz AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>149E710A7C4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E8CDD51-9D39-4DE5-9589-F8F2F96F3BFF</gtr:id><gtr:title>Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2e893673af806c3cb89c50d861de13e4"><gtr:id>2e893673af806c3cb89c50d861de13e4</gtr:id><gtr:otherNames>Kaplan DE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>4695BAE6B56</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>01E82921-95E0-4A7B-B87C-D2423E5D8223</gtr:id><gtr:title>Buccals are likely to be a more informative surrogate tissue than blood for epigenome-wide association studies.</gtr:title><gtr:parentPublicationTitle>Epigenetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/06ecc980f6bf446c46971c57333c2641"><gtr:id>06ecc980f6bf446c46971c57333c2641</gtr:id><gtr:otherNames>Lowe R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1559-2294</gtr:issn><gtr:outcomeId>585d5a6b503bc5.02838995</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>722D1A25-FB40-4E52-A079-FBDF6D695EE8</gtr:id><gtr:title>Structural characterization of CD81-Claudin-1 hepatitis C virus receptor complexes.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/47a7e0c1a30cbdc3c9114d7bc4876109"><gtr:id>47a7e0c1a30cbdc3c9114d7bc4876109</gtr:id><gtr:otherNames>Bonander N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>pm_15282_22_21428935</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D13063BC-DC0B-4A99-8DF0-57E448FD0C1A</gtr:id><gtr:title>Differential effect of p7 inhibitors on hepatitis C virus cell-to-cell transmission.</gtr:title><gtr:parentPublicationTitle>Antiviral research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a2b568e567c92b96b0359b6a2750e89"><gtr:id>3a2b568e567c92b96b0359b6a2750e89</gtr:id><gtr:otherNames>Meredith LW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0166-3542</gtr:issn><gtr:outcomeId>pm_15282_22_24157306</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE3934A6-771A-4767-8D61-9ED455619B45</gtr:id><gtr:title>Hepatitis C virus entry and the tetraspanin CD81.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb70ad6cf6f738ae40b6d445174549c8"><gtr:id>eb70ad6cf6f738ae40b6d445174549c8</gtr:id><gtr:otherNames>Farquhar MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>pm_15282_22_21428934</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3491C72-04E6-43A0-80C9-EBF7C95130B1</gtr:id><gtr:title>Age-associated hyper-methylated regions in the human brain overlap with bivalent chromatin domains.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c5fb3a941e77ca8f5476abcbc141ecad"><gtr:id>c5fb3a941e77ca8f5476abcbc141ecad</gtr:id><gtr:otherNames>Watson CT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>585d5a8d6ac705.92114179</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AAC92CE2-3B27-474B-B1D7-2AAEF0BD2B03</gtr:id><gtr:title>Guthrie card methylomics identifies temporally stable epialleles that are present at birth in humans.</gtr:title><gtr:parentPublicationTitle>Genome research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aaeb29cc1c94a3d6b48a6426ed307e09"><gtr:id>aaeb29cc1c94a3d6b48a6426ed307e09</gtr:id><gtr:otherNames>Beyan H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1088-9051</gtr:issn><gtr:outcomeId>585d5a9b48d549.07090991</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE627DB6-C540-467E-A16B-6161AE76D004</gtr:id><gtr:title>Multiple sclerosis: risk factors and their interactions.</gtr:title><gtr:parentPublicationTitle>CNS &amp; neurological disorders drug targets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af39e4662c93fc98be2a0468db12b545"><gtr:id>af39e4662c93fc98be2a0468db12b545</gtr:id><gtr:otherNames>Disanto G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1871-5273</gtr:issn><gtr:outcomeId>585d5a9e870933.80851715</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A378529-2AD8-405A-B1CB-0769CA3E6BA3</gtr:id><gtr:title>Early infection events highlight the limited transmissibility of hepatitis C virus in vitro.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a2b568e567c92b96b0359b6a2750e89"><gtr:id>3a2b568e567c92b96b0359b6a2750e89</gtr:id><gtr:otherNames>Meredith LW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>pm_15282_22_23353869</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD555398-2679-4D00-9941-D125C1C85F4C</gtr:id><gtr:title>Hepatitis C virus infection of neuroepithelioma cell lines.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e28545930847fbdf21015e10fbfd11d1"><gtr:id>e28545930847fbdf21015e10fbfd11d1</gtr:id><gtr:otherNames>Fletcher NF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>RCvdbqNugWZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A727CAD2-9F67-4D1B-B29D-D4454C8E571D</gtr:id><gtr:title>Mechanisms of viral entry: sneaking in the front door.</gtr:title><gtr:parentPublicationTitle>Protoplasma</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c6aa76591c16a0efc9a1c55289404af6"><gtr:id>c6aa76591c16a0efc9a1c55289404af6</gtr:id><gtr:otherNames>Thorley JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0033-183X</gtr:issn><gtr:outcomeId>J9GbqLYxnMt</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C6BE440-A281-4291-BB96-760588FD6EA4</gtr:id><gtr:title>Genomic regions associated with multiple sclerosis are active in B cells.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af39e4662c93fc98be2a0468db12b545"><gtr:id>af39e4662c93fc98be2a0468db12b545</gtr:id><gtr:otherNames>Disanto G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>585d5abce5cf78.72969171</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>534A9B99-0F24-4E6D-90FF-6959FBDF9848</gtr:id><gtr:title>Seasonal distribution of psychiatric births in England.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af39e4662c93fc98be2a0468db12b545"><gtr:id>af39e4662c93fc98be2a0468db12b545</gtr:id><gtr:otherNames>Disanto G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5a360be22ca195.24885272</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7443F430-10A0-428D-B589-AE0DEEDC7EC1</gtr:id><gtr:title>Hepatitis C virus entry and neutralization.</gtr:title><gtr:parentPublicationTitle>Clinics in liver disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc3759cd1489c0e1829b6d5b6d53c0b7"><gtr:id>fc3759cd1489c0e1829b6d5b6d53c0b7</gtr:id><gtr:otherNames>Stamataki Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1089-3261</gtr:issn><gtr:outcomeId>18587536F1D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C7BADCE-F9B6-4F74-B6E1-B94E77A6DF47</gtr:id><gtr:title>A new panel of epitope mapped monoclonal antibodies recognising the prototypical tetraspanin CD81.</gtr:title><gtr:parentPublicationTitle>Wellcome open research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe40ce492da64d8686da83c7038b7e65"><gtr:id>fe40ce492da64d8686da83c7038b7e65</gtr:id><gtr:otherNames>Grove J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2398-502X</gtr:issn><gtr:outcomeId>5a2fd686ab7d17.93512529</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A0D994BC-BA3E-4FD3-8F28-5024DC1673B0</gtr:id><gtr:title>Protein-protein interaction analysis highlights additional loci of interest for multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5f60749d0066cd6b191555398fff0650"><gtr:id>5f60749d0066cd6b191555398fff0650</gtr:id><gtr:otherNames>Ragnedda G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>585d5a8a717735.18652938</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF2754FD-7883-41B8-B69B-1E5BC733DF62</gtr:id><gtr:title>Primary hepatocytes as targets for hepatitis C virus replication.</gtr:title><gtr:parentPublicationTitle>Journal of viral hepatitis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb70ad6cf6f738ae40b6d445174549c8"><gtr:id>eb70ad6cf6f738ae40b6d445174549c8</gtr:id><gtr:otherNames>Farquhar MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1352-0504</gtr:issn><gtr:outcomeId>ndERCX6tbyc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0D249E30-52DA-4AD3-B587-CD9845A5F5AD</gtr:id><gtr:title>Hepatitis C virus induces CD81 and claudin-1 endocytosis.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb70ad6cf6f738ae40b6d445174549c8"><gtr:id>eb70ad6cf6f738ae40b6d445174549c8</gtr:id><gtr:otherNames>Farquhar MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_15282_22_22318146</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CA636599-AB22-4462-AB69-A12DC0D6586C</gtr:id><gtr:title>Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d9e444d2922dd043f966085965c94caa"><gtr:id>d9e444d2922dd043f966085965c94caa</gtr:id><gtr:otherNames>Mee CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>BQUVteRfakE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5489CF7B-9059-43AA-845C-3E57C9445660</gtr:id><gtr:title>Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d20aac3bd0b3b0b09dda180803b31989"><gtr:id>d20aac3bd0b3b0b09dda180803b31989</gtr:id><gtr:otherNames>Timpe JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>589A565491A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35FBA93F-07D3-4827-A9AA-D1956F813F36</gtr:id><gtr:title>An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32940939798776e174a016529546b916"><gtr:id>32940939798776e174a016529546b916</gtr:id><gtr:otherNames>Handel AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>585d5ade640365.86024030</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>57B7A293-DC05-4748-902C-7D85E8C2C9D9</gtr:id><gtr:title>In vitro selection of a neutralization-resistant hepatitis C virus escape mutant.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9aaf9275375c857c4f9d98d2eb2ea67b"><gtr:id>9aaf9275375c857c4f9d98d2eb2ea67b</gtr:id><gtr:otherNames>Gal-Tanamy M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>3951BFD600D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A02E5A4-CE53-4500-A276-910135440D6F</gtr:id><gtr:title>EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c37da01b6bb7122f1c13b7a56c29b906"><gtr:id>c37da01b6bb7122f1c13b7a56c29b906</gtr:id><gtr:otherNames>Lupberger J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>Tp7fnkBTGdb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>400AB7CB-1A4F-4FF6-9C7A-7CA655EEB9C8</gtr:id><gtr:title>Sex ratio of infectious mononucleosis and possible relevance to multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Multiple sclerosis (Houndmills, Basingstoke, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b76c8aca5550da4a9dad29ded472960"><gtr:id>9b76c8aca5550da4a9dad29ded472960</gtr:id><gtr:otherNames>Ramagopalan SV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1352-4585</gtr:issn><gtr:outcomeId>585d5aa099c140.29913891</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6C376C36-B66E-48FB-A79E-B1A4905CEB42</gtr:id><gtr:title>The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis.</gtr:title><gtr:parentPublicationTitle>Multiple sclerosis (Houndmills, Basingstoke, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63e5b7621621fb6aaaf3c2def012af64"><gtr:id>63e5b7621621fb6aaaf3c2def012af64</gtr:id><gtr:otherNames>Pakpoor J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1352-4585</gtr:issn><gtr:outcomeId>585d5aa3486f19.56397085</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4C9D162-B6CE-4F34-90CC-CE820077A998</gtr:id><gtr:title>Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/462130645d338d72568c32df2d9660bb"><gtr:id>462130645d338d72568c32df2d9660bb</gtr:id><gtr:otherNames>Evans MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>D147E5AD653</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9375D8AF-0482-468D-8DC6-AB0ABA2A938F</gtr:id><gtr:title>Role of the HLA system in the association between multiple sclerosis and infectious mononucleosis.</gtr:title><gtr:parentPublicationTitle>Archives of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b76c8aca5550da4a9dad29ded472960"><gtr:id>9b76c8aca5550da4a9dad29ded472960</gtr:id><gtr:otherNames>Ramagopalan SV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0003-9942</gtr:issn><gtr:outcomeId>585d5ad75830c4.89645669</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D01D18F1-7AD5-4079-95C8-1869AFB6735B</gtr:id><gtr:title>Development of novel therapies for hepatitis C.</gtr:title><gtr:parentPublicationTitle>Antiviral research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8ef2a2b91bf143dfecdce236f5e4de6e"><gtr:id>8ef2a2b91bf143dfecdce236f5e4de6e</gtr:id><gtr:otherNames>Lemon SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0166-3542</gtr:issn><gtr:outcomeId>DLGXpE6kCYh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2FE70C53-C804-484E-A420-3C6D29937356</gtr:id><gtr:title>The refinement of genetic predictors of multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af39e4662c93fc98be2a0468db12b545"><gtr:id>af39e4662c93fc98be2a0468db12b545</gtr:id><gtr:otherNames>Disanto G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>585d59e8e449b1.04484233</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>970CE77C-AF11-4FF3-865B-A98B813E6F31</gtr:id><gtr:title>Hepatitis C virus envelope glycoprotein fitness defines virus population composition following transmission to a new host.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e5bc1756e96e835a0772ea0b6c44eaa"><gtr:id>3e5bc1756e96e835a0772ea0b6c44eaa</gtr:id><gtr:otherNames>Brown RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_15282_22_22855498</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3CDB75A5-3B2F-4070-8E1D-D1631B41BA79</gtr:id><gtr:title>Production, purification and characterization of recombinant, full-length human claudin-1.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/47a7e0c1a30cbdc3c9114d7bc4876109"><gtr:id>47a7e0c1a30cbdc3c9114d7bc4876109</gtr:id><gtr:otherNames>Bonander N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_15282_22_23704991</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B91E4945-A9B1-4702-847D-EB21117A7E04</gtr:id><gtr:title>Epstein-Barr virus, latitude and multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Multiple sclerosis (Houndmills, Basingstoke, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af39e4662c93fc98be2a0468db12b545"><gtr:id>af39e4662c93fc98be2a0468db12b545</gtr:id><gtr:otherNames>Disanto G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1352-4585</gtr:issn><gtr:outcomeId>5a361052a2c783.33564952</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>927468DF-2A92-4D8D-B945-DEC6E0C3180B</gtr:id><gtr:title>Protein kinase A-dependent step(s) in hepatitis C virus entry and infectivity.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb70ad6cf6f738ae40b6d445174549c8"><gtr:id>eb70ad6cf6f738ae40b6d445174549c8</gtr:id><gtr:otherNames>Farquhar MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>02D2C8A4D88</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89EC4561-0048-44A6-AB62-D1DE2628B18D</gtr:id><gtr:title>Expression of DC-SIGN and DC-SIGNR on human sinusoidal endothelium: a role for capturing hepatitis C virus particles.</gtr:title><gtr:parentPublicationTitle>The American journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e1e35a161241c08af0a83743707122f7"><gtr:id>e1e35a161241c08af0a83743707122f7</gtr:id><gtr:otherNames>Lai WK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0002-9440</gtr:issn><gtr:outcomeId>2ADC9904341</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D97093A-E558-434E-88A1-DD02D9B875CC</gtr:id><gtr:title>Regulatory genomic regions active in immune cell types explain a large proportion of the genetic risk of multiple sclerosis.</gtr:title><gtr:parentPublicationTitle>Journal of human genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b69d9af3d9917826a07840f25f23b8f4"><gtr:id>b69d9af3d9917826a07840f25f23b8f4</gtr:id><gtr:otherNames>Elangovan RI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1434-5161</gtr:issn><gtr:outcomeId>585d59fe2c29d0.77446888</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A89A9D7-6EBA-4A38-A8D3-89B2DD361798</gtr:id><gtr:title>Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a784b2046abed7a3dc95b54864208b67"><gtr:id>a784b2046abed7a3dc95b54864208b67</gtr:id><gtr:otherNames>Molina S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>F682212F2A3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B2ADCDB-D4BC-4A78-8244-EB890D5EB5F3</gtr:id><gtr:title>In silico directed mutagenesis identifies the CD81/claudin-1 hepatitis C virus receptor interface.</gtr:title><gtr:parentPublicationTitle>Cellular microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7db0f8aa3dff74a26cb87933de072153"><gtr:id>7db0f8aa3dff74a26cb87933de072153</gtr:id><gtr:otherNames>Davis C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1462-5814</gtr:issn><gtr:outcomeId>pm_15282_22_22897233</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>27CABD35-30A1-468C-99AD-FC7FD1E3ACDC</gtr:id><gtr:title>Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/095dbbaf878d75dcdb302c7affaa8f40"><gtr:id>095dbbaf878d75dcdb302c7affaa8f40</gtr:id><gtr:otherNames>Syder AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>kJoHtys9txH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0FC6A414-07B2-48FE-B59B-3987259D9A2C</gtr:id><gtr:title>Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe40ce492da64d8686da83c7038b7e65"><gtr:id>fe40ce492da64d8686da83c7038b7e65</gtr:id><gtr:otherNames>Grove J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>1F2B5F21866</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A385CC4-8961-4DB7-AA37-353325A2FFA6</gtr:id><gtr:title>Effect of cell polarization on hepatitis C virus entry.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d9e444d2922dd043f966085965c94caa"><gtr:id>d9e444d2922dd043f966085965c94caa</gtr:id><gtr:otherNames>Mee CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>D1BCEB202FB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB8B056A-A20E-4D10-9DAD-E5564AE62920</gtr:id><gtr:title>Deep sequencing of hepatitis C virus reveals genetic compartmentalization in cerebrospinal fluid from cognitively impaired patients.</gtr:title><gtr:parentPublicationTitle>Liver international : official journal of the International Association for the Study of the Liver</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d84a8ec626304bd46399f5c70de06714"><gtr:id>d84a8ec626304bd46399f5c70de06714</gtr:id><gtr:otherNames>Tully DC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1478-3223</gtr:issn><gtr:outcomeId>58b5554e40ef86.09171928</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F702B4E-D245-4DF8-AF35-702548FAC138</gtr:id><gtr:title>Hepatitis C virus entry: possible targets for therapy.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d20aac3bd0b3b0b09dda180803b31989"><gtr:id>d20aac3bd0b3b0b09dda180803b31989</gtr:id><gtr:otherNames>Timpe JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>4353E4ED931</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3008820-FA5A-42E1-880E-4B426289B192</gtr:id><gtr:title>Hepatitis C virus and the brain.</gtr:title><gtr:parentPublicationTitle>Journal of viral hepatitis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e28545930847fbdf21015e10fbfd11d1"><gtr:id>e28545930847fbdf21015e10fbfd11d1</gtr:id><gtr:otherNames>Fletcher NF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1352-0504</gtr:issn><gtr:outcomeId>pm_15282_22_22497808</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97DCD6AE-C7AA-4124-A475-CB06C8E15CDF</gtr:id><gtr:title>Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eb70ad6cf6f738ae40b6d445174549c8"><gtr:id>eb70ad6cf6f738ae40b6d445174549c8</gtr:id><gtr:otherNames>Farquhar MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>58b555856aed16.73568455</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>324B64D7-299A-439C-88DF-B0EB552EA224</gtr:id><gtr:title>Hepatitis C virus entry: beyond receptors.</gtr:title><gtr:parentPublicationTitle>Reviews in medical virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a2b568e567c92b96b0359b6a2750e89"><gtr:id>3a2b568e567c92b96b0359b6a2750e89</gtr:id><gtr:otherNames>Meredith LW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1052-9276</gtr:issn><gtr:outcomeId>pm_15282_22_22392805</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1943E938-B176-4C75-B6BC-145D8CECE86A</gtr:id><gtr:title>Type I interferon rapidly restricts infectious hepatitis C virus particle genesis.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a2b568e567c92b96b0359b6a2750e89"><gtr:id>3a2b568e567c92b96b0359b6a2750e89</gtr:id><gtr:otherNames>Meredith LW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>54593752635ac0.16616216</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4C3B1286-3472-4F8B-8481-D9747F8687BE</gtr:id><gtr:title>Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fba3ccb5d5fdeb9fdfc12cfe1fdc3142"><gtr:id>fba3ccb5d5fdeb9fdfc12cfe1fdc3142</gtr:id><gtr:otherNames>Tarr AW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_15282_22_22171278</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D39707B-3827-42F7-8B4B-B0E502D479AF</gtr:id><gtr:title>Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ae3b8b0391d7478fd888d57135e3f37e"><gtr:id>ae3b8b0391d7478fd888d57135e3f37e</gtr:id><gtr:otherNames>Keck ZY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>B10A9BA8D55</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E92B34F4-5D31-46D0-A0A9-BBBF6C31C197</gtr:id><gtr:title>Entry of hepatitis B and C viruses - recent progress and future impact.</gtr:title><gtr:parentPublicationTitle>Current opinion in virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/363ad5d61c060939ed60a0c5465c493f"><gtr:id>363ad5d61c060939ed60a0c5465c493f</gtr:id><gtr:otherNames>Baumert TF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1879-6257</gtr:issn><gtr:outcomeId>54593751897c65.47800284</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>18E6B1D8-CCBC-4A98-A198-C35062BCA90D</gtr:id><gtr:title>Hepatitis C virus targets the T cell secretory machinery as a mechanism of immune evasion.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6cfdb8ffc54679f2f25831b0dfd61977"><gtr:id>6cfdb8ffc54679f2f25831b0dfd61977</gtr:id><gtr:otherNames>Petrovic D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>Jgbz26TCaKv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>838B3224-C2AB-47A1-BA31-A2F4BF519DAF</gtr:id><gtr:title>Month of birth, vitamin D and risk of immune-mediated disease: a case control study.</gtr:title><gtr:parentPublicationTitle>BMC medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af39e4662c93fc98be2a0468db12b545"><gtr:id>af39e4662c93fc98be2a0468db12b545</gtr:id><gtr:otherNames>Disanto G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1741-7015</gtr:issn><gtr:outcomeId>5a63660f258101.44947225</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EBE2C59C-143C-49E9-A496-614968F53404</gtr:id><gtr:title>Hepatitis C virus association with peripheral blood B lymphocytes potentiates viral infection of liver-derived hepatoma cells.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc3759cd1489c0e1829b6d5b6d53c0b7"><gtr:id>fc3759cd1489c0e1829b6d5b6d53c0b7</gtr:id><gtr:otherNames>Stamataki Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>986B024AA54</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE6DA1B4-E483-4CC8-9FAB-BB8A71684180</gtr:id><gtr:title>Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a5bded635fcd0ab8d05007017a49ea62"><gtr:id>a5bded635fcd0ab8d05007017a49ea62</gtr:id><gtr:otherNames>Fofana I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>UQqf2HfGABa</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>061B5865-FDAA-4304-B149-DF1E0B040456</gtr:id><gtr:title>Vitamin D supplementation and antibodies against the Epstein-Barr virus in multiple sclerosis patients.</gtr:title><gtr:parentPublicationTitle>Multiple sclerosis (Houndmills, Basingstoke, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af39e4662c93fc98be2a0468db12b545"><gtr:id>af39e4662c93fc98be2a0468db12b545</gtr:id><gtr:otherNames>Disanto G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1352-4585</gtr:issn><gtr:outcomeId>585d5a48060e07.86443390</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7991AA62-8276-43F3-AAF3-AE2657781E72</gtr:id><gtr:title>Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90b707b0a82725422ada99831ecc90b7"><gtr:id>90b707b0a82725422ada99831ecc90b7</gtr:id><gtr:otherNames>Lake-Bakaar G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>D416F4435FC</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>93BD4C26-3E89-4DF5-8305-F749662BA3EC</gtr:id><gtr:title>Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb4ab0f7d7971e405dfa06672fdb1cf3"><gtr:id>cb4ab0f7d7971e405dfa06672fdb1cf3</gtr:id><gtr:otherNames>Lindenbach BD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>13F8690BE4F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A8AE0E93-2BBB-4DA3-B142-5B61A1C6FFAC</gtr:id><gtr:title>Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef440b91f08c078acac798192ced855f"><gtr:id>ef440b91f08c078acac798192ced855f</gtr:id><gtr:otherNames>Krieger SE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>nqJX2h6eQ5V</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21B9CDB2-279C-412E-91BD-3751A20052F1</gtr:id><gtr:title>Hepatitis C virus infection of cholangiocarcinoma cell lines.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e28545930847fbdf21015e10fbfd11d1"><gtr:id>e28545930847fbdf21015e10fbfd11d1</gtr:id><gtr:otherNames>Fletcher NF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>5675dff8c1e5c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD473599-1C4B-4660-BE67-4460099938EA</gtr:id><gtr:title>In vitro veritas? The challenges of studying hepatitis C virus infectivity in a test tube.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d6940caa80bc023cd10f951b128d76eb"><gtr:id>d6940caa80bc023cd10f951b128d76eb</gtr:id><gtr:otherNames>von Hahn T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>3D693B26A39</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CFE5294-219E-49BE-A355-9FC843131D37</gtr:id><gtr:title>Hypoxia inducible factors in liver disease and hepatocellular carcinoma: current understanding and future directions.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a7463d1f8fa86587b5c95fd20445a75"><gtr:id>1a7463d1f8fa86587b5c95fd20445a75</gtr:id><gtr:otherNames>Wilson GK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>545937528d8546.70767065</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7106E2F-2FB1-4C7A-9856-52CEA0DFD5C7</gtr:id><gtr:title>Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation.</gtr:title><gtr:parentPublicationTitle>Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68859e2678f8b3f51bdc173b90573c7b"><gtr:id>68859e2678f8b3f51bdc173b90573c7b</gtr:id><gtr:otherNames>Rowe IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1527-6465</gtr:issn><gtr:outcomeId>56cddd210c5370.98820982</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>975E7167-ED82-48F4-8EE9-F482A08135CE</gtr:id><gtr:title>Hepatitis C is associated with perturbation of intrahepatic myeloid and plasmacytoid dendritic cell function.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e1e35a161241c08af0a83743707122f7"><gtr:id>e1e35a161241c08af0a83743707122f7</gtr:id><gtr:otherNames>Lai WK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>8B6600983E9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40DF937B-AD52-4DA0-B08E-C2FB1CB2DE48</gtr:id><gtr:title>Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross-neutralize heterologous virus strains.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc3759cd1489c0e1829b6d5b6d53c0b7"><gtr:id>fc3759cd1489c0e1829b6d5b6d53c0b7</gtr:id><gtr:otherNames>Stamataki Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>jhngn21PSD8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C94E1CE-7EC8-4304-974B-C53F028C2C3F</gtr:id><gtr:title>Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a003248c37cce8d7df973b7017f3354f"><gtr:id>a003248c37cce8d7df973b7017f3354f</gtr:id><gtr:otherNames>Mizukoshi E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>68B83A125E4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>49E70019-C428-4CBB-A6C5-FFBADA87D9EA</gtr:id><gtr:title>Hepatoma polarization limits CD81 and hepatitis C virus dynamics.</gtr:title><gtr:parentPublicationTitle>Cellular microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72c9d36662cb20471af6a26537b90de2"><gtr:id>72c9d36662cb20471af6a26537b90de2</gtr:id><gtr:otherNames>Harris HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1462-5814</gtr:issn><gtr:outcomeId>pm_15282_22_23126643</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5ABAC93-090C-4C6B-841D-4998C95BF788</gtr:id><gtr:title>An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fba3ccb5d5fdeb9fdfc12cfe1fdc3142"><gtr:id>fba3ccb5d5fdeb9fdfc12cfe1fdc3142</gtr:id><gtr:otherNames>Tarr AW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>pm_15282_22_23553604</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>50FA6F18-7905-465D-A791-19E2B30684C9</gtr:id><gtr:title>Adaptive Mutations Enhance Assembly and Cell-to-Cell Transmission of a High-Titer Hepatitis C Virus Genotype 5a Core-NS2 JFH1-Based Recombinant.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ffb3d69db62b4506befe77f9713c06f7"><gtr:id>ffb3d69db62b4506befe77f9713c06f7</gtr:id><gtr:otherNames>Mathiesen CK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>5675e4eb8b58c</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9316842-1B84-4CE4-8050-14EE2F1B5566</gtr:id><gtr:title>Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d9e444d2922dd043f966085965c94caa"><gtr:id>d9e444d2922dd043f966085965c94caa</gtr:id><gtr:otherNames>Mee CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>6A1C527DA11</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD145AAB-EC89-4985-BE09-895F19EE6CB9</gtr:id><gtr:title>Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bdfb66698bf12de7c9639a895d0cb7e8"><gtr:id>bdfb66698bf12de7c9639a895d0cb7e8</gtr:id><gtr:otherNames>Law M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>836CA2CC6EE</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F2BEACB5-B4C8-43D1-B5F4-D46E1215FF37</gtr:id><gtr:title>Permissivity of primary hepatocytes and hepatoma cell lines to support hepatitis C virus infection.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a7463d1f8fa86587b5c95fd20445a75"><gtr:id>1a7463d1f8fa86587b5c95fd20445a75</gtr:id><gtr:otherNames>Wilson GK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>5675df95d1db2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EBAE3D07-601B-44B6-A73E-46075BC48DEE</gtr:id><gtr:title>A role for CD81 and hepatitis C virus in hepatoma mobility.</gtr:title><gtr:parentPublicationTitle>Viruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/55308829b0f2e78b8deb7e8dbd9a471c"><gtr:id>55308829b0f2e78b8deb7e8dbd9a471c</gtr:id><gtr:otherNames>Brimacombe CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1999-4915</gtr:issn><gtr:outcomeId>545937523aa714.94986106</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6BB933E4-DDFE-4F00-824C-EF7E4579DA10</gtr:id><gtr:title>Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/77ddc2fb2a78327bb10beb12110e4d7d"><gtr:id>77ddc2fb2a78327bb10beb12110e4d7d</gtr:id><gtr:otherNames>Kapadia SB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>8C82842E0E2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>539D76C3-25A2-49E0-9F37-606281CDE551</gtr:id><gtr:title>Hepatitis C virus infects the endothelial cells of the blood-brain barrier.</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e28545930847fbdf21015e10fbfd11d1"><gtr:id>e28545930847fbdf21015e10fbfd11d1</gtr:id><gtr:otherNames>Fletcher NF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>pm_15282_22_22138189</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FDBD3191-5BC5-4720-B640-C42D72F3A0F2</gtr:id><gtr:title>Inactive or moderately active human promoters are enriched for inter-individual epialleles.</gtr:title><gtr:parentPublicationTitle>Genome biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa89f677740715b1b949f81435d7eaa7"><gtr:id>aa89f677740715b1b949f81435d7eaa7</gtr:id><gtr:otherNames>Gemma C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1474-7596</gtr:issn><gtr:outcomeId>585d5a5e98c808.36322216</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>707FB107-E93E-4745-85EB-51BD590D7360</gtr:id><gtr:title>Claudin association with CD81 defines hepatitis C virus entry.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72c9d36662cb20471af6a26537b90de2"><gtr:id>72c9d36662cb20471af6a26537b90de2</gtr:id><gtr:otherNames>Harris HJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>FvsU4mm8geR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C36073AA-25A0-44E4-B81E-672FEE043635</gtr:id><gtr:title>Smoking and multiple sclerosis: an updated meta-analysis.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32940939798776e174a016529546b916"><gtr:id>32940939798776e174a016529546b916</gtr:id><gtr:otherNames>Handel AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>585d5ad9eed0d9.60941044</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2DF9A480-BA41-45E9-8CDB-07011688CD3F</gtr:id><gtr:title>Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ff4c4c49807475824c370c30580373b"><gtr:id>0ff4c4c49807475824c370c30580373b</gtr:id><gtr:otherNames>Tscherne DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>8127D34634E</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BAD780E5-4F09-4081-AB11-34F2D2EC6AA7</gtr:id><gtr:title>Structural characterization of recombinant human CD81 produced in Pichia pastoris.</gtr:title><gtr:parentPublicationTitle>Protein expression and purification</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b08d2b7f9fc00bcd87fca83ab5372507"><gtr:id>b08d2b7f9fc00bcd87fca83ab5372507</gtr:id><gtr:otherNames>Jamshad M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1046-5928</gtr:issn><gtr:outcomeId>6E833DA3A26</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90D21942-21C7-4DEA-BE0C-DB48CEB8566F</gtr:id><gtr:title>Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/55308829b0f2e78b8deb7e8dbd9a471c"><gtr:id>55308829b0f2e78b8deb7e8dbd9a471c</gtr:id><gtr:otherNames>Brimacombe CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>kizQrUy44Lu</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B8DBAA66-6B57-47FF-B804-4C4BD97BE5E1</gtr:id><gtr:title>A dual role for hypoxia inducible factor-1a in the hepatitis C virus lifecycle and hepatoma migration.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a7463d1f8fa86587b5c95fd20445a75"><gtr:id>1a7463d1f8fa86587b5c95fd20445a75</gtr:id><gtr:otherNames>Wilson GK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>pm_15282_22_22178269</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>75D0A719-2564-44EB-8C1D-5AE8EB68D9D4</gtr:id><gtr:title>TNF superfamily members promote hepatitis C virus entry via an NF-?B and myosin light chain kinase dependent pathway.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e28545930847fbdf21015e10fbfd11d1"><gtr:id>e28545930847fbdf21015e10fbfd11d1</gtr:id><gtr:otherNames>Fletcher NF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>58b5554e6fcf35.78693952</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2D024874-9F7B-408C-A481-5DC989D3EA70</gtr:id><gtr:title>High resolution sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end-stage liver disease.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc69287aca943f9da74db554607d91d4"><gtr:id>fc69287aca943f9da74db554607d91d4</gtr:id><gtr:otherNames>Hedegaard DL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>5a35e34038a321.50887883</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E658F69-68A0-4019-A360-B1268E0E48E6</gtr:id><gtr:title>Rituximab treatment in hepatitis C infection: an in vitro model to study the impact of B cell depletion on virus infectivity.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc3759cd1489c0e1829b6d5b6d53c0b7"><gtr:id>fc3759cd1489c0e1829b6d5b6d53c0b7</gtr:id><gtr:otherNames>Stamataki Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>RoL1oQ4eQQK</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801976</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>